Icon (NASDAQ:ICLR) Posts Earnings Results, Misses Expectations By $0.62 EPS

Icon (NASDAQ:ICLR) released its quarterly earnings data on Wednesday. The medical research company reported $2.52 EPS for the quarter, missing analysts’ consensus estimates of $3.14 by ($0.62), FiscalAI reports. The firm had revenue of $2.11 billion for the quarter, compared to analyst estimates of $1.98 billion. Icon had a return on equity of 10.58% and a net margin of 7.40%.The company’s quarterly revenue was up 2.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.43 earnings per share. Icon updated its FY 2026 guidance to 10.000-11.000 EPS.

Icon Stock Up 4.0%

Shares of NASDAQ ICLR opened at $118.45 on Thursday. Icon has a 12-month low of $66.57 and a 12-month high of $211.00. The company has a market cap of $9.57 billion, a P/E ratio of 16.03, a P/E/G ratio of 2.97 and a beta of 1.23. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31. The stock has a fifty day moving average price of $111.55 and a 200 day moving average price of $141.66.

Institutional Trading of Icon

Large investors have recently added to or reduced their stakes in the stock. EFG International AG acquired a new stake in Icon in the 4th quarter valued at $27,000. Johnson Financial Group Inc. acquired a new stake in shares of Icon during the third quarter valued at about $71,000. Quadrant Capital Group LLC acquired a new stake in shares of Icon during the third quarter valued at about $78,000. Geneos Wealth Management Inc. grew its stake in shares of Icon by 11.5% during the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock valued at $79,000 after acquiring an additional 56 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB grew its stake in shares of Icon by 198.8% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 487 shares of the medical research company’s stock valued at $89,000 after acquiring an additional 324 shares in the last quarter. 95.61% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ICLR has been the subject of a number of research analyst reports. Bank of America restated an “underperform” rating and set a $105.00 price objective on shares of Icon in a report on Wednesday. Barclays dropped their price objective on Icon from $200.00 to $120.00 and set an “equal weight” rating for the company in a report on Monday, March 9th. Citigroup dropped their price objective on Icon from $200.00 to $120.00 and set a “neutral” rating for the company in a report on Wednesday, March 11th. Rothschild & Co Redburn set a $100.00 price objective on Icon and gave the stock a “neutral” rating in a report on Tuesday, February 17th. Finally, JPMorgan Chase & Co. lowered their price target on Icon from $175.00 to $120.00 and set a “neutral” rating for the company in a report on Monday, May 18th. Seven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $147.67.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.